CLAIMS

1. A pharmaceutical composition for bacterial infections and wound healing, the pharmaceutical composition comprising:
   - a topical antibiotic pharmaceutically active agent;
   - a biopolymer, wherein the biopolymer is Chitosan,
   - hydrolysed collagen of type I; and
   - an ointment base;

   wherein the components are mixed homogeneously to form an ointment of pH value between 6.8 and 7.2,
   wherein the topical antibiotic pharmaceutically active agent is Mupirocin present in an amount between 0.1% (w/w) to 5% (w/w),
   wherein the Chitosan is present in an amount between 0.01% (w/w) to 0.5% (w/w), and
   wherein the hydrolysed collagen of type I is present in an amount between 0.01 (w/w) to 0.5% (w/w).

2. The pharmaceutical composition as claimed in claim 1, wherein the Mupirocin is present in an amount of 2% (w/w).

3. The pharmaceutical composition as claimed in claim 1, wherein the Chitosan is present in an amount of 0.05% (w/w).

4. The pharmaceutical composition as claimed in claim 1, wherein the hydrolysed collagen of type I is present in an amount of 0.05% (w/w).

5. The pharmaceutical composition as claimed in claim 1, wherein the ointment base comprises:
   - waxy materials selected from a group comprising Polyethylene Glycols (PEG), PEG 400, PEG 500, PEG 1000, PEG 1200, PEG 1500, PEG 1800, PEG 2000, PEG 2200, PEG 3550, PEG 4000, and any combination thereof, and present in an amount between 5% (w/w) to 80% (w/w),
   - co-solvents selected from a group comprising Propylene Glycol, Hexylene Glycol, PEG 200, PEG 300, PEG 400, and PEG 500, and present in an amount between 5% (w/w) to 80% (w/w),
   - acids selected from a group comprising HCl, H_2SO_4, HNO_3, and Lactic acid and present in an amount between 0.005% (w/w) to 1% (w/w),
   - thickeners selected from a group comprising Acrylamide/Sodium AcryloyldimethylTaurate Copolymer/Isohexadecane&Polysorbate 80 (Brand Name – Sepineo™ P 600), Microcrystalline Cellulose, Carboxymethyl Cellulose, HydroxypropylMethylCellulose,

EthylCellulose, and any combination thereof, and present in an amount between 0.05% (w/w) to 10% (w/w),

- preservatives selected from a group comprising Methylparaben, Propylparaben, Chlorocresol, Potassium sorbate, Benzyl Alcohol, and Phenoxyethanol, and present in an amount between 0.05% (w/w) to 2.0 % (w/w),
- chelating agents comprising Disodium EDTA and present in an amount substantially of 0.01% (w/w) or between 0.05% (w/w) to 1% (w/w), and
- water present in an amount substantially of 2% (w/w).

6. The pharmaceutical composition as claimed in any of claims 1 to 5, wherein the Chitosan has a degree of deacetylation of no less than 70%.

7. The pharmaceutical composition as claimed in any of claims 1 to 5, wherein the Chitosan has a degree of deacetylation of no less than 80%.

8. The pharmaceutical composition as claimed in any of claims 1 to 7, wherein the Chitosan has a bacterial endotoxin level of 100 IU/g.

9. The pharmaceutical composition as claimed in any of claims 1 to 8, wherein the Chitosan has a molecular weight between 250,000 Da to 600,000 Da.

10. The pharmaceutical composition as claimed in any of claims 1 to 9, wherein the hydrolysed collagen has a molecular weight between 3 kDa to 6 kDa.